Arbutus Biopharma Corporation (ABUS) AI Stock Analysis

Arbutus Biopharma Corporation is a biopharmaceutical firm based in Warminster, Pennsylvania, focused on therapies for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. Its pipeline includes AB-729, a subcutaneously administered GalNAc-delivered RNA interference candidate, and AB-836, an oral capsid inhibitor. The company is also pursuing preclinical programs such as AB-161, an oral HBV RNA destabilizer, and AB-101, an oral PD-L1 inhibitor. Additionally, it develops small molecule antivirals against coronaviruses and maintains strategic alliances, licensing agreements, and research collaborations with partners including Talon Therapeutics, Gritstone Oncology, and Alnylam Pharmaceuticals.

Between FY2021 and FY2025, Arbutus Biopharma experienced significant revenue swings, moving from $11.0M in FY2021 up to $39.0M in FY2022, down to $6.2M in FY2024, and rebounding 128.2% to $14.1M in FY2025. Across this span, the five-year revenue CAGR from FY2020 to FY2025 was 15.3%. Operating margins were consistently negative, reaching -192.1% in FY2025 alongside a net loss of -$33.5M and an EPS of -$0.24. Over the trailing twelve months, revenue totaled $181.7M with a net profit margin of 84.2% and EPS of $0.79. However, the latest quarter ended June 30, 2026, saw quarterly revenue decline 90.6% year-over-year.

As of June 30, 2026, Arbutus Biopharma held $92.6M in cash and short-term investments against total debt of $3.6M, resulting in net cash of $89.0M. Shareholders' equity was $258.7M, supporting a debt-to-equity ratio of 0.01 and a current ratio of 81.42. Cash generation has historically been negative; FY2025 operating cash flow was -$39.6M and free cash flow was -$39.6M, which improved from -$65.0M in FY2024. Over the past five years, the company's share count increased 95.0%.

At a share price of $4.22, Arbutus Biopharma holds a market capitalization of $646.8M and an enterprise value of $868.7M. The stock trades at a trailing P/E of 5.3x and a forward P/E of 10.2x, compared to medians of 24.6x and 17.3x, respectively, for its US-listed Healthcare peers. Its enterprise value to EBITDA ratio stands at 5.9x, below the peer group median of 12.0x. Over the past year, the stock returned -6.4%, underperforming the S&P 500 (SPY) return of 16.8%.

One analyst covers Arbutus Biopharma with a Strong Buy rating. The mean price target of $5.40 implies an upside of 27.9% from the last closing price of $4.22. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $252.8M and EPS of $1.03. For the following fiscal year, 1 analyst projects revenue to contract to $5.7M and EPS to decline to -$0.11. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Arbutus Biopharma Corporation (ABUS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ABUS income statement, ABUS balance sheet, ABUS key metrics, ABUS analyst forecast, ABUS chart. See the ABUS stock overview for the latest quote and news.